These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17192126)

  • 21. Comparing HMG-CoA reductase inhibitors.
    Jones PH
    Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I15-20. PubMed ID: 12539818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperlipidemia in older adults.
    Aslam F; Haque A; Lee LV; Foody J
    Clin Geriatr Med; 2009 Nov; 25(4):591-606, vii. PubMed ID: 19944263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Statins--attaining goal values--with reference to recent studies].
    Toplak H; Schallmoser K; DeCampo A
    Wien Med Wochenschr; 1999; 149(5-6):144-5. PubMed ID: 10408006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive lipid-lowering therapy and regression of coronary atheroma.
    Rajaram K
    JAMA; 2004 Jul; 292(1):39; author reply 39-40. PubMed ID: 15238582
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
    Kerst LL; Mauro VF
    Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 31. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
    [No Abstract]   [Full Text] [Related]  

  • 32. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Wieland H
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 35. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving role of statins in the management of atherosclerosis.
    Vaughan CJ; Gotto AM; Basson CT
    J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins.
    Ferrières J
    Am J Cardiovasc Drugs; 2009; 9(2):109-15. PubMed ID: 19331439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.